WO2002056876A3 - Treatment for snoring - Google Patents

Treatment for snoring Download PDF

Info

Publication number
WO2002056876A3
WO2002056876A3 PCT/US2002/001353 US0201353W WO02056876A3 WO 2002056876 A3 WO2002056876 A3 WO 2002056876A3 US 0201353 W US0201353 W US 0201353W WO 02056876 A3 WO02056876 A3 WO 02056876A3
Authority
WO
WIPO (PCT)
Prior art keywords
snoring
treatment
azelastine
antihistamine
salt
Prior art date
Application number
PCT/US2002/001353
Other languages
French (fr)
Other versions
WO2002056876A2 (en
Inventor
Thomas Alan Halvorson
Original Assignee
Medpointe Healthcare Inc
Thomas Alan Halvorson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medpointe Healthcare Inc, Thomas Alan Halvorson filed Critical Medpointe Healthcare Inc
Priority to AU2002236781A priority Critical patent/AU2002236781A1/en
Publication of WO2002056876A2 publication Critical patent/WO2002056876A2/en
Publication of WO2002056876A3 publication Critical patent/WO2002056876A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicinal Preparation (AREA)

Abstract

Use of an antihistamine, in particular azelastine (or salt thereof) for alleviating snoring.
PCT/US2002/001353 2001-01-18 2002-01-17 Treatment for snoring WO2002056876A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002236781A AU2002236781A1 (en) 2001-01-18 2002-01-17 Treatment for snoring

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26244901P 2001-01-18 2001-01-18
US60/262,449 2001-01-18

Publications (2)

Publication Number Publication Date
WO2002056876A2 WO2002056876A2 (en) 2002-07-25
WO2002056876A3 true WO2002056876A3 (en) 2002-11-14

Family

ID=22997558

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/001353 WO2002056876A2 (en) 2001-01-18 2002-01-17 Treatment for snoring

Country Status (2)

Country Link
AU (1) AU2002236781A1 (en)
WO (1) WO2002056876A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7107992B2 (en) 2002-10-04 2006-09-19 Pavad Medical, Inc. System and method for preventing closure of passageways
US7882842B2 (en) 2004-09-21 2011-02-08 Pavad Medical, Inc. Airway implant sensors and methods of making and using the same
US8578937B2 (en) 2004-09-21 2013-11-12 Medtronic Xomed, Inc. Smart mandibular repositioning system
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
PL2486942T3 (en) 2004-11-24 2019-05-31 Meda Pharmaceuticals Inc Compositions comprising azelastine and methods of use thereof
US20160008334A1 (en) * 2013-03-05 2016-01-14 Requis Pharmaceuticals Inc. Preparations for the Treatment of Sleep-Related Respiratory Disorders
EP3061501A1 (en) 2015-02-27 2016-08-31 Rottapharm Ltd. Composition for the treatment of acne
EP3117825A1 (en) 2015-07-16 2017-01-18 Rottapharm S.p.A. Oral formulation comprising berberine and morus alba extract
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11744833B2 (en) * 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0316633A1 (en) * 1987-11-13 1989-05-24 ASTA Medica Aktiengesellschaft Medicine containing azelastine for application in the nose and/or at the eye

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0316633A1 (en) * 1987-11-13 1989-05-24 ASTA Medica Aktiengesellschaft Medicine containing azelastine for application in the nose and/or at the eye

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
COREY J.P. ET AL: "Nasal Congestion: A Review of its Etiology, Evaluation, and Treatment", EAR, NOSE AND THROAT JOURNAL, vol. 79, no. 9, 2000, pages 690 - 704, XP001096088 *
HAGEL E.: "Upper Airways and Bronchial Diseases. Early Detection in Childhood and Preventive Measures", ATEMWEGS- UND LUNGENKRANKHEITEN, vol. 21, no. suppl. 1, 1995, pages S10-S13, XP001097925 *
PHILLIPS, B. ET AL: "When is Snoring Clinically Significant?", JOURNAL OF RESPIRATORY DISEASES, vol. 18, no. 2, 1997, pages 181 - 193, XP001097932 *
SCHARF M.B. ET AL: "Diagnostic and Treatment Implications of Nasal Obstruction in Snoring and Obstructive Sleep Apnea", ANNALS OF ALLERGY, ASTHMA AND IMMUNOLOGY, vol. 81, no. 4, 1998, pages 279 - 290, XP001097984 *

Also Published As

Publication number Publication date
AU2002236781A1 (en) 2002-07-30
WO2002056876A2 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
AU2003299791A1 (en) Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
AU2002339157A1 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
AU2003281978A1 (en) 2,5-diketopiperazines for the treatment of obesity
AP2006003525A0 (en) Ä1,8ÜNapthyridin-2-ones and related compounds for the treatment of schizophrenia.
AU2003254038A1 (en) Glyconjugates comprising carbohydrate epitopes, methods for theirsynthesis, and their use for the treatment or prophylaxis of cancer
AU2003206785A1 (en) Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
AU2002362895A1 (en) 5-carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
HK1068335A1 (en) Novel arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
ZA200500323B (en) Use of lkb kinase inhibitors for the treatment of pain.
AU2002346929A1 (en) 5-acylamino-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
AU2003289888A1 (en) Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders
WO2003088897A3 (en) Fab i inhibitors
AU2002342613A1 (en) Treatment for wounds
AU2002364300A1 (en) Polymer derivatives for the treatment of metals
AUPR839001A0 (en) Dosage form, device and methods of treatment
AP2004002997A0 (en) Heterocyclic compounds for use in the treatment ofdisorders of the urinary tract.
AU2003219100A1 (en) Pyrazolopyridazine derivatives, process for preparation and use for the inhibition of gsk-3
AU2001253070A1 (en) Isoflavones for treatment of obesity
WO2002056876A3 (en) Treatment for snoring
AU2003263760A1 (en) Methods for the treatment or prevention of obesity
MXPA02012907A (en) Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity.
AU2003291886A1 (en) Thiophenederivatives for the treatment of flavivirus infections
AU2003297363A1 (en) Use of cathepsin k inhibitors for the treatment of glaucoma
AU2003287445A1 (en) Compounds, methods and devices for inhibiting neoproliferative changes in blood vessel walls
AU2003266960A1 (en) Composition for the treatment of pain, especially for the treatment of articular pain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP